Aegle Therapeutics has proprietary technology for extracellular vesicle isolation. The U.S. Food and Drug Administration (FDA) cleared the company's first Investigational New Drug (IND) application to begin clinical trials in burn patients in 2018.The Phase 1/2a study includes severe second degree burn patients and will evaluate the safety of extracellular vesicle therapy and is an open label dose escalation protocol in patients at several sites in the United States.
Aegle's extracellular vesicles isolated from MSCs, called AGLE-102, are claimed to have potential to enhance healing, reduce scarring, minimize contraction and improve overall cosmesisfor patients with burns who suffer scarring, disfigurement, loss of mobility and chronic pain.
On May 1, 2018 Aegle Therapeutics completed their seed funding round with and undisclosed amount of funding from Ocean Azul Partners.
2018 Drug Development Pipeline Review for Dermatological Burns, Scars and Ulcers - Features MediWound, Aegle Therapeutics, NovaLead Pharma, and many more
Research and Markets
October 18, 2019
Aegle Therapeutics hopes to treat rare pediatric skin disorder
January 10, 2019
Aegle Therapeutics receives IND clearance from FDA for stem cell-derived extracellular vesicle therapy
Exosome RNA Administrator
Florida Startups, Tech Investors Already Feel Sting of State Budget Cuts